By Robb M. Stewart
Furthermore, Health Canada has received a submission from Pfizer and partner BioNTech, seeking approval for their own Covid-19 vaccine for the same subvariant and age group. Additionally, Novavax has submitted its vaccine targeting the Omicron XBB.1.5 subvariant for individuals aged 12 and older.
In evaluating Moderna's latest vaccine, known as Spikevax, Health Canada has determined that it meets all safety, efficacy, and quality requirements.
According to the product label of Moderna's Spikevax, individuals aged five years and older should receive one dose of the vaccine, regardless of their Covid-19 vaccination history. For children between six months and four years old, two doses are recommended if they have not previously received a Covid-19 vaccine. However, if they have already had one or more prior doses of a Covid-19 vaccine, a single dose is sufficient.
Health Canada's approval follows the clearance of updated boosters by the U.S. Food and Drug Administration for individuals aged six months and older. Advisors to the Centers for Disease Control and Prevention are expected to endorse these latest Covid-19 boosters later today.
